Table 1 Comparison of key subgroups in Checkmate 141 and KEYNOTE 040 trials
Nivolumab | SOC | SOC | Pembrolizumab | |
|---|---|---|---|---|
n = 240 | n = 121 | n = 248 | n = 247 | |
≥3 prior lines | 19,9 | 1,2 | ||
PD-L1 TPS ≥ 1% (%) | 37,0 | 50,0 | 77,0 | 79,4 |
PD-L1 TPS ≥ 50% (%) | – | – | 26,2 | 25,9 |
HPV+ (%) | 26,0 | 24,0 | 23,4 | 24,7 |
ECOG-0 (%) | 20,0 | 19,0 | 17,0 | 19,0 |
ORR (%) | 13,0 | 6,0 | 10,1 | 14,6 |
mPFS (mo.) | 2,0 | 2,3 | 2,3 | 2,1 |
OS HR (CI95%) | 0,70 (0,51-0,96) | 0,80 (0,65-0,98) | ||
P = 0,01 | P = 0,0161 | |||
mOS (mo.) | 7,5 | 5,1 | 6,9 | 8,4 |
1y-OS rate | 0,4 | 0,2 | 0,3 | 0,4 |